People · Operator
Named in public records as an officer, director or promoter · active 2011–2023 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Relievant MedSystems Inc | — | Other Health Care | Series C | $200.1M | $522.9M | 2023 |
| Second Genome, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2011 |
Jason Lettmann at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jason Lettmann on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Ryan | 1 | 17 |
| Corey Goodman | 1 | 13 |
| Brent Ahrens | 1 | 7 |
| Michael Carusi | 1 | 7 |
| Ross Jaffe | 1 | 7 |
| Justin Klein | 1 | 6 |
| David Amerson | 1 | 5 |
| Peter Klein | 1 | 5 |
| Kevin Hykes | 1 | 4 |
| ARTHUR TAYLOR | 1 | 4 |
| Richard Mott | 1 | 3 |
| Matthew Winkler | 1 | 3 |
| Peter DiLaura | 1 | 3 |
| Art Taylor | 1 | 3 |
| Alexander Schmitz | 1 | 2 |
| Alex DiNello | 1 | 2 |
| Jason Lettman | 1 | 2 |
| Chris Geyen | 1 | 2 |
| Peter Gardner | 1 | 2 |
| Ray Baker, MD | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.